Therapy Detail

Therapy Name Docetaxel + Plinabulin
Therapy Description


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Docetaxel Taxotere Docetaxel anhydrous|Docefrez Antimicrotubule Agent 11 Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (NCI Drug Dictionary).
Plinabulin NPI-2358 Antimicrotubule Agent 11 Plinabulin is a diketopiperazine derivative that disrupts microtubule organization, leading to cell cycle arrest in tumor cells and collapse of tumor vasculature (PMID: 16317287).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown non-small cell lung carcinoma not applicable Docetaxel + Plinabulin Phase I Actionable In a Phase I clinical trial, Plinabulin and Taxotere (docetaxel) combination treatment resulted in partial response in 25% (2/8) and minor improvement in 50% (4/8) of patients with non-small cell lung cancer (PMID: 21327495). 21327495
Clinical Trial Phase Therapies Title Recruitment Status
NCT02504489 Phase III Docetaxel Docetaxel + Plinabulin Plinabulin (P) + Docetaxel (D) vs D as 2nd-Line Chemo in Patients With Advanced NSCLC With at Least 1 Large Lung Lesion Recruiting